Shire Release: Firazyr®: First Subcutaneous Treatment For Acute Attacks Of Rare And Serious Swelling Disorder Now Available In Canada

MONTRÉAL, July 17, 2014 /CNW/ - Shire Canada Inc. ("Shire") announced today the availability of FIRAZYR® (icatibant injection) in Canada for the treatment of acute attacks of hereditary angioedema (HAE) in adults with C1-esterase inhibitor deficiency. Firazyr is the first and only subcutaneous, ready-to-use option available to Canadians living with the rare and serious disorder.

Help employers find you! Check out all the jobs and post your resume.